NLS and Kadimastem stocks soar following merger agreement

By Yahoo! Finance | Nov 5, 2024 at 12:53 PM EST

Switzerland's NLS Pharmaceutics and Israel's Kadimastem are merging to create a joint biopharmaceutical focusing on neurogenerative diseases and diabetes treatments. The merger deal includes stock issuance to Kadimastem shareholders, and both companies plan to divest some assets.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.